Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 10, 2007, Pages 564-565

  Heist, Rebecca S ^a   Liu, Geoffrey ^b,c   Zhou, Wei ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM; RIBONUCLEOTIDE REDUCTASE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; DISEASE FREE SURVIVAL; ENZYME SUBUNIT; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEDICAL SPECIALIST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; TISSUE MICROARRAY;

EID: 35148889051     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0909     Document Type: Short Survey

References (5)

1. Olaussen KA et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991
2. Potti A et al. (2006) A genomic strategy to refine prognosis in early stage non-small cell lung cancer. N Engl J Med 355: 570-580
3. Chen HY et al. (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356: 11-20
4. Bepler G et al. (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24: 4731-4737
5. Rosell R et al. (2005) ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p) [abstract #7002]. J Clin Oncol 23 (Suppl 16S part I)